Clinical trial · no report yet · Phase 1/Phase 2
NCT05410145
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- NCT05410145 ↗
- Recruiting
- D3 Bio (Wuxi) Co., Ltd
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- KRAS P.G12C
- Interventions
- D3S-001; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Cetuximab
- Arms
- D3S-001 monotherapy · Experimental
- D3S-001 and pembrolizumab · Experimental
- D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + pemetrexed) · Experimental
- D3S-001 and Cetuximab · Experimental
- Enrollment
- 442 (estimated)
- Primary outcomes
- Number of Participants With Adverse Events (AEs)
- Number of Participants With Dose-Limiting Toxicities (DLTs)
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
- Start
- Aug 3, 2022
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05410145 · updated Sep 15, 2026
Publications
linked from the registry- Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial. Nat Med. 2025 Aug;31(8):2768-2777. doi: 10.1038/s41591-025-03688-6. Epub 2025 Apr 29. PubMed 40301557